Loopbaan van Robert Freisen
Eerdere bekende functies van Robert Freisen
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ABLYNX | Hoofd Techniek/Wetenschap/O&O | 01-03-2018 | 01-01-2019 |
| PROQR THERAPEUTICS N.V. | Corporate Officer/Principal | 01-01-2016 | 01-01-2018 |
| Janssen Biotherapeutics | Corporate Officer/Principal | 01-01-2008 | 01-01-2014 |
| MORPHOSYS AG | Corporate Officer/Principal | - | - |
Opleiding van Robert Freisen
| University of Utrecht | Undergraduate Degree |
| The University of Texas at Austin | Doctorate Degree |
Statistieken
Internationaal
| België | 3 |
| Nederland | 3 |
| Duitsland | 2 |
Operationeel
| Corporate Officer/Principal | 3 |
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| PROQR THERAPEUTICS N.V. | Health Technology |
| MORPHOSYS AG | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Ablynx NV
 Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
| Janssen Biotherapeutics |
- Beurs
- Insiders
- Robert Freisen
- Ervaring
